This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Are you a student entering pharmacy school? In this video, I’ll talk about my 4 steps to have success in pharmacy school. Stay until the end for my most important step. Watch & Subscribe on our YouTube Channel ! [link]. Hi, I’m Dr. Jessica Louie and I’m an Associate Professor, Board-Certified Critical Care Pharmacist and entrepreneur. I help people find meaning beyond a job title and let go of burnout.
The move to online international meetings has left pharma companies with uncertainty around contact compliance. But new joint guidance, from the IFPMA, EFPIA, and PhRMA, provides clarity. To say the world of work has changed is something of an understatement in the pharma and biopharma industry. Since COVID-19 reared its head more than two years ago, the traditional hustle and bustle of in-person annual congresses have largely been consigned to the history books.
Are you going to launch a new business by partnering with a new PCD Pharma Company ? Or do you want to expand your business by adding one more company? In both situations, you should be careful and selective while choosing a company. There are several companies around when you search for it. But it is always good to associate with the best one. Why should you prefer the best company?
Most pharma and biopharma executives agree the patient voice should be at the centre of everything they do. But for many, it is a prospect that remains much easier said than done. A lack of defined processes for the collection and sharing of insights across the drug development cycle has hampered the industry’s good intentions and, in some cases, turned engagement into an empty box-ticking exercise.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Northway Biotech, a contract development and manufacturing organization (CDMO) based out of Vilnius, Lithuania, is set to open a facility in Boston, US.
Shares in US biotech Verrica Pharma lost half their value today after the FDA declined to approve its candidate treatment for viral skin infection molluscum contagiosum for a third time. The problems outlined in the US regulator’s complete response letter (CRL) for VP-102 centre around contract manufacturing organisation (CMO) Sterling Pharmaceuticals Services, which is producing VP-102 for Verrica.
Physicians and other healthcare professionals are trained to care for others. It’s what we do. In dedicating our lives to caring for others, self-care comes last, and we often put ourselves on the back burner. During training, and in our careers, the default mode is that our own needs come last. That’s embedded into our medical culture. . What if we shifted our focus and treated ourselves as well as we treat those who we love most in the world?
52
52
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Physicians and other healthcare professionals are trained to care for others. It’s what we do. In dedicating our lives to caring for others, self-care comes last, and we often put ourselves on the back burner. During training, and in our careers, the default mode is that our own needs come last. That’s embedded into our medical culture. . What if we shifted our focus and treated ourselves as well as we treat those who we love most in the world?
Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals’ etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble seems to have paid off. Yesterday, the company reported the results of the two trials of the S1P receptor modulator in patients with moderately-to-severely active UC at the Digestive Disease Week congress, with the data suggesting it could mount a strong challenge against rival Zeposia (ozanimod)
Michelle Keefe, formerly the president of medical affairs and commercial solutions, joined the company in 2017; she also had spent 20 years working for Pfizer.
Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in the treatment of the skin disorder. Vtama (tapinarof) – originally developed by GlaxoSmithKline – is a first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA) and has been approved by the US regulator with a broad label spanning mild, moderate, and severe psoriasis and an
The DATAcc has released a collection of open-access resources that are intended to help users build inclusivity into digital health measurement products.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
On May 13, 2022, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Mounjaro (tirzepatide), a once-weekly injection for the treatment of type 2 diabetes mellitus (T2DM). Pathophysiology of Type 2 Diabetes Mellitus Incretins are the hormones that are released by the body in response to a meal. There are two key […]. The post Tirzepatide Clinical Breakdown appeared first on Med Ed 101.
After more than six years of development, Angle has scored an FDA approval for Parsortix as a diagnostic for metastatic breast cancer – the first ever in the US for a device used to detect cancer by harvesting cells from a patient blood sample. In a statement , the UK medical device firm said its “liquid biopsy” approach “offers the prospect of a new era of personalised cancer care” and moves it closer to positioning Parsortix as a go-to technology for assessing cancer st
Around 100 patients in England and Wales with triple negative breast cancer (TNBC) that has spread to other parts of the body could soon access treatment with Merck & Co/MSD’s Keytruda, on the recommendation of cost-effectiveness agency NICE. The health technology assessment (HTA) body has published draft guidance supporting routine NHS use of Keytruda (pembrolizumab) along with chemotherapy in patient with metastatic TNBC whose tumours express the biomarker PD-L1 with a combine positi
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
US pharma giant Pfizer has said it will sell some of its patented medicines at non-profit prices to 45 of the world’s poorest countries – including new launches. The initiative will focus on infectious diseases, cancer, inflammation, rare diseases and women’s health, and will include its BioNTech-partnered COVID-19 vaccine Comirnaty as well as oral antiviral therapy Paxlovid (nirmatrelvir/ritonavir).
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content